Lupus Erythematosus, Systemic Clinical Trial
— SLE-HIITOfficial title:
Effects of High-intensity Interval Training Combined With Resistance Training in Patients With Systemic Lupus Erythematosus
The aim of this study is to evaluate the safety and effects of high-intensity interval training (HIIT) combined with resistance training in patients with systemic lupus erythematosus
Status | Recruiting |
Enrollment | 40 |
Est. completion date | December 31, 2026 |
Est. primary completion date | June 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - =18 years old - Fulfilment of the 1982 American College of Rheumatology (ACR) criteria; or 2012 Systemic Lupus International Collaborating Clinics (SLICC/ACR-Damage Index (DI)) classification criteria; or EULAR/ACR criteria; or patients that have received the diagnosis SLE on clinical grounds - Low to moderate disease activity, for example defined as a score of =5 in the clinical version of the SLE Disease Activity Index 2000 (SLEDAI-2K), i.e., excluding the serological descriptors (anti-dsDNA positivity and low complement levels) - Low/minimal or no organ damage, for example defined as a score of =3 in the SLICC/ACR DI - Stable pharmacological treatment - The ability to perform a maximal ergometercycle exercise test - Be able to read and understand Swedish Exclusion Criteria: - Symptoms or signs of cerebro-vascular disease, pulmonary embolus, pulmonary hypertension, pulmonary fibrosis, cardiovascular disease, angina pectoris, myocardial infarction, dyspnea at rest, uncontrolled blood pressure and uncontrolled diabetes within one year prior to study entry. Chronic kidney disease with - Patients who fulfil the absolute contraindications for maximal exercise testing according to American Heart Association - Patients who cannot perform a maximal ergometercycle exercise test due to the disease - Diseases or other conditions that strongly reduce the ability to exercise or that exercise is not recommended - Patients who perform regular aerobic fitness training and muscle strength exercise sessions at fixed times, >1 time/week - Pregnancy |
Country | Name | City | State |
---|---|---|---|
Sweden | Carina Boström | Stockholm | Huddinge |
Lead Sponsor | Collaborator |
---|---|
Karolinska Institutet | County Council of Norrbotten, Sweden, Karolinska University Hospital, Region Örebro County, Swedish Rheumatism Association |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Organ damage | Systemic Lupus International Collaborating Clinics (SLICC/ACR-Damage Index). Organ damage last 6 months, assessed by a physician. The points goes from 0-47, the higher the value, the more organ damage | Baseline and 6 months | |
Other | Demographical, clinical and lifestyle behaviour data including age, gender, ethnic origin, and smoking status as well as other for the project important information about the disease such as autoantibody profiles and pharmacological treatment | A questionnaire developed specific for this project and data from patients medical files | Baseline. For some variables, such as medical treatment, also months 3 and 6 | |
Other | Physical activity | The patient-reported questionnaire International Physical Activity Questionnaire addresses the number of days and time spent on physical activity in moderate intensity, vigorous intensity and walking of at least 10-min duration the last 7 days, and also includes time spent sitting on weekdays the last 7 days. The sum score is expressed in physical activity Metabolic Equivalent of Task-minutes per day or week | Baseline, months 3 and 6 | |
Other | Activity-minutes and sitting behaviour | The patient-reported questions about Activity-minutes and sitting behaviour according to the Swedish National Board of Health and Welfare. For the two questions about physical training and exercise with 5 respective 6 answer alternatives, the higher the value, the more time spending training and exercising. The question about sitting have 7 answer alternatives, the higher the value, the less time spent sitting | Baseline, months 3 and 6 | |
Other | Weight | Weight in kilograms | Baseline, months 3 and 6 | |
Other | Height | Height in meters | Baseline | |
Other | Body Mass Index (BMI) | Weight in kilograms divided by the height in metres squared | Baseline, months 3 and 6 | |
Other | Muscle function lower extremity | How many times is it possible to raise from a chair during 30 seconds; the "30 seconds Chair stand test" | Baseline, months 3 and 6 | |
Primary | Aerobic capacity | Aerobic capacity is measured as maximal oxygen uptake when performing a maximal symptom-limited, ergometercycle exercise test | Baseline, months 3 and 6 | |
Primary | Physical capacity | Physical capacity are measured when performing a symptom-limited, ergometercycle exercise test | Baseline, months 3 and 6 | |
Secondary | Muscle function upper extremity | How many shoulder flexions (0-90 degrees), in a given pace, with a 3 kg (men) or 2 kg (women) dumbbell in the hand is possible to do | Baseline, months 3 and 6 | |
Secondary | Self-reported disease activity | The patient-reported questionnaire Systemic Lupus Erythematosus Activity Questionnaire includes three parts. The part about disease symptoms goes from 0-47 points, the higher the points the more disease symptoms. Further there is a question about flares with four answer alternatives, from no flares to serious flares. There is also a numerical rating scale about disease activity on a scale from 0-10, the higher value the higher the disease activity | Baseline, months 3 and 6 | |
Secondary | Fatigue | The patient-reported questionnaire Functional Assessment of Chronic Illness Therapy, FACIT-Fatigue goes from 0-52 points, the higher the value, the less the fatigue | Baseline, months 3 and 6 | |
Secondary | Anxiety and depressive symptoms | The patient-reported questionnaire Hospital Anxiety and Depression scale goes from 0-21 points, the higher the value, the higher the anxiety and depressive symptoms. In the anxiety and depressive symptoms subscales the points goes from 0-6, the higher the value, the higher anxiety and depressive symptoms respectively | Baseline, months 3 and 6 | |
Secondary | Quality of life in SLE | The patient-reported questionnaire Lupus Quality of life questionnaire goes from 0-100 points, the higher the value the better the quality of life | Baseline, months 3 and 6 | |
Secondary | Generic Quality of life | The patient-reported questionnaire Short Form Health Survey (SF-36). Each subscale goes from 0-100 points, the higher the value, the higher the quality of life. | Baseline, months 3 and 6 | |
Secondary | Quality of life and health status | The patient-reported questionnaire EuroQol 5-dimensions (EQ-5D). The index scores goes from -0,594 till 1,000, the higher the value, the higher the quality of life | Baseline, months 3 and 6 | |
Secondary | Disease activity | SLE Disease Activity Index 2000 (SLEDAI-2K) assessed by a physician, goes from 0-105 points, the higher the value, the higher the disease activity | Baseline, months 3 and 6 | |
Secondary | Inflammatory markers | Blood samples are collected before and after maximal ergometercycle exercise test | Baseline, months 3 and 6 | |
Secondary | Health status | The patient-reported questionnaire EuroQol 5-dimensions (EQ-5D)-5L Visual analogue scale, 0-100 mm, the higher the value, the better the health | Baseline, months 3 and 6 | |
Secondary | Blood pressure | Resting diastolic and systolic blood pressure | Baseline, month 3 and 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Recruiting |
NCT05967520 -
JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT02875691 -
Effect of Green Tea on Treatment of Lupus
|
Phase 2 | |
Completed |
NCT02922114 -
Comparison of the Clinical Examination and the Joint Ultrasonography in Lupus Patients
|
N/A | |
Withdrawn |
NCT01702038 -
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
|
Phase 2 | |
Terminated |
NCT00368264 -
TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )
|
Phase 2/Phase 3 | |
Completed |
NCT00094380 -
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
|
Phase 1/Phase 2 | |
Completed |
NCT00065806 -
Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
|
Phase 3 | |
Completed |
NCT00005436 -
Lupus Cohort--Thrombotic Events and Coronary Artery Disease
|
N/A | |
Recruiting |
NCT03543839 -
Trial of Belimumab in Early Lupus
|
Phase 4 | |
Completed |
NCT03098823 -
A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE
|
Phase 4 | |
Recruiting |
NCT05899907 -
Efficacy and Safety of Telitacicept in Early SLE
|
Phase 4 | |
Completed |
NCT04956484 -
Belimumab In Early Systemic Lupus Erythematosus
|
Phase 4 | |
Completed |
NCT05326841 -
Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients .
|
Phase 3 | |
Completed |
NCT02655640 -
The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis
|
N/A | |
Completed |
NCT02034344 -
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
|
Phase 0 | |
Terminated |
NCT00089804 -
Study of LJP 394 in Lupus Patients With History of Renal Disease
|
Phase 3 | |
Completed |
NCT00071487 -
Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
|
Phase 2 | |
Completed |
NCT02349061 -
A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
|
Phase 2 | |
Recruiting |
NCT05636670 -
Assessment of Cognitive Function and Gut Microbiota Analysis in Real World Patients With Lupus Cerebrovascular Disease
|